BAT2606 vs Mepolizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: IL-5 · full Asthma pipeline
BAT2606
Developed by Bio-Thera Solutions
NCT05576454 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Cmax (Day1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 22, 29, 43, 57, 71, 85, 99, 113); AUC0-∞ (Day1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 22, 29, 43, 57, 71, 85, 99, 113): In 207 subjects enrolled and randomized, the 90% confidence intervals of the geometric mean ratios of maximum concentration and area under the curve from time 0 to infinity were within 80.00%-125.00%. (met)
Result source: NCT05576454
Mepolizumab · Nucala
Marketed by GlaxoSmithKline
NCT01691859 · Phase 3 · completed
This was an open-label, single-arm long-term extension of the prior MEA112997 trial, enrolling 347 participants who had received at least two doses in that study. Because there was no randomization, blinding, or control group, the primary safety endpoint was descriptive rather than a comparative efficacy test, although the explicit extension design provides follow-up evidence beyond the original randomized trial. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants Who Experienced On-treatment Adverse Events (AE) and On-treatment Serious Adverse Events (SAE)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66 (met)
Result source: NCT01691508
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BAT2606 | Mepolizumab |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | 0.5 vs 1.3−0.9 vs placeboNCT035621955 other results
|
| Trough FEV1, change | —Not reported | —Not reported |
| ACQ-5, change | —Not reported | -0.8 vs -0.4−0.4 vs placeboNCT02281318 |
| OCS dose reduction | —Not reported | -50% vs 0%−50 vs placeboNCT016915081 other result
|
Severe exacerbations, annualised rate
- BAT2606
- —Not reported
- Mepolizumab
- 0.5 vs 1.3−0.9 vs placeboNCT03562195
5 other results
- 0.8 vs 1.7 NCT01691521
- 0.9 vs 1.7 NCT01691521
- 1.2 vs 2.4 NCT01000506
- 1.1 vs 2.4 NCT01000506
- 1.5 vs 2.4 NCT01000506
Trough FEV1, change
- BAT2606
- —Not reported
- Mepolizumab
- —Not reported
ACQ-5, change
- BAT2606
- —Not reported
- Mepolizumab
- -0.8 vs -0.4−0.4 vs placeboNCT02281318
OCS dose reduction
- BAT2606
- —Not reported
- Mepolizumab
- -50% vs 0%−50 vs placeboNCT01691508
1 other result
- 83.8% vs 47.7% NCT00292877
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. BAT2606: 0 of 4 rows · Mepolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Mepolizumab |
|---|---|
| Dropout rate | n/a: no completion milestone100 mga NCT01691859 · Phase 3 · monotherapy show 37 more results—Mepolizumab NCT01691859 · Phase 3 · monotherapy 15.7%75 mg IV NCT01000506 · Phase 2 14.7%750 mg IV NCT01000506 · Phase 2 13.8%250 mg IV NCT01000506 · Phase 2 —100 mg SC NCT01691508 · Phase 3 2.1%100 mg NCT04823585 · Phase 4 · registry result, not featured evidence 0% NCT04765722 · Phase 4 · registry result, not featured evidence 10%100 mg SC NCT04276233 · Phase 4 · registry result, not featured evidence 4.8%100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence 2.7%100 mg NCT03562195 · Phase 3 · registry result, not featured evidence 3.6%100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 1.3% NCT03099096 · Phase 3 · registry result, not featured evidence n/a: no completion milestone100 mg SC NCT02135692 · Phase 3 · registry result, not featured evidence 0%Liquid Autoinjector NCT03014674 · Phase 3 · registry result, not featured evidence 0%Liquid Safety Syringe NCT03014674 · Phase 3 · registry result, not featured evidence 1.2%Lyophilized Vial NCT03014674 · Phase 3 · registry result, not featured evidence 1.8% NCT03021304 · Phase 3 · registry result, not featured evidence 1.8%100 mg NCT02281318 · Phase 3 · registry result, not featured evidence —100 mg SC NCT02281318 · Phase 3 · registry result, not featured evidence 10.1%100 mg SC NCT01842607 · Phase 3 · registry result, not featured evidence 4.6%100 mg SC NCT01691521 · Phase 3 · registry result, not featured evidence 8.4%75 mg IV NCT01691521 · Phase 3 · registry result, not featured evidence 13.7% NCT03292588 · Phase 2 · registry result, not featured evidence 0%100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —40/100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 15.4%40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 0%75 mg IV NCT01366521 · Phase 2 · registry result, not featured evidence 8.7%250 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 6.7%125 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 4.8%12.5 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 73.7% NCT00802438 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 5.5%100 mga NCT01691859 · Phase 3 · monotherapy show 37 more results—Mepolizumab NCT01691859 · Phase 3 · monotherapy 3.3%75 mg IV NCT01000506 · Phase 2 5.8%750 mg IV NCT01000506 · Phase 2 5.3%250 mg IV NCT01000506 · Phase 2 —100 mg SC NCT01691508 · Phase 3 —100 mg NCT04823585 · Phase 4 · registry result, not featured evidence — NCT04765722 · Phase 4 · registry result, not featured evidence 1%100 mg SC NCT04276233 · Phase 4 · registry result, not featured evidence —100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence 0%100 mg NCT03562195 · Phase 3 · registry result, not featured evidence 0.3%100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 0.6% NCT03099096 · Phase 3 · registry result, not featured evidence 0.9%100 mg SC NCT02135692 · Phase 3 · registry result, not featured evidence —Liquid Autoinjector NCT03014674 · Phase 3 · registry result, not featured evidence —Liquid Safety Syringe NCT03014674 · Phase 3 · registry result, not featured evidence —Lyophilized Vial NCT03014674 · Phase 3 · registry result, not featured evidence — NCT03021304 · Phase 3 · registry result, not featured evidence 0.7%100 mg NCT02281318 · Phase 3 · registry result, not featured evidence —100 mg SC NCT02281318 · Phase 3 · registry result, not featured evidence 1.7%100 mg SC NCT01842607 · Phase 3 · registry result, not featured evidence 0.5%100 mg SC NCT01691521 · Phase 3 · registry result, not featured evidence 0%75 mg IV NCT01691521 · Phase 3 · registry result, not featured evidence — NCT03292588 · Phase 2 · registry result, not featured evidence —100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —40/100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 0%75 mg IV NCT01366521 · Phase 2 · registry result, not featured evidence 0%250 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 0%125 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 4.8%12.5 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence — NCT00802438 · Phase na · registry result, not featured evidence |
| Serious AEs | —100 mga NCT01691859 · Phase 3 · monotherapy show 37 more results22.8%Mepolizumab NCT01691859 · Phase 3 · monotherapy 13.1%75 mg IV NCT01000506 · Phase 2 12.2%750 mg IV NCT01000506 · Phase 2 15.8%250 mg IV NCT01000506 · Phase 2 1.4%100 mg SC NCT01691508 · Phase 3 4.3%100 mg NCT04823585 · Phase 4 · registry result, not featured evidence 0% NCT04765722 · Phase 4 · registry result, not featured evidence 3%100 mg SC NCT04276233 · Phase 4 · registry result, not featured evidence 11%100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence 12.1%100 mg NCT03562195 · Phase 3 · registry result, not featured evidence 2.3%100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 6.3%100mg NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 8.9%100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 11.9%100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 2.5% NCT03099096 · Phase 3 · registry result, not featured evidence 24.8%100 mg SC NCT02135692 · Phase 3 · registry result, not featured evidence 0%Liquid Autoinjector NCT03014674 · Phase 3 · registry result, not featured evidence 0%Liquid Safety Syringe NCT03014674 · Phase 3 · registry result, not featured evidence 0%Lyophilized Vial NCT03014674 · Phase 3 · registry result, not featured evidence 5.4% NCT03021304 · Phase 3 · registry result, not featured evidence —100 mg NCT02281318 · Phase 3 · registry result, not featured evidence 5.5%100 mg SC NCT02281318 · Phase 3 · registry result, not featured evidence 14.4%100 mg SC NCT01842607 · Phase 3 · registry result, not featured evidence 8.2%100 mg SC NCT01691521 · Phase 3 · registry result, not featured evidence 7.3%75 mg IV NCT01691521 · Phase 3 · registry result, not featured evidence 2.7% NCT03292588 · Phase 2 · registry result, not featured evidence 10%100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 20%100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 25%40/100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 19.2%40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 25%40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 0%75 mg IV NCT01366521 · Phase 2 · registry result, not featured evidence 0%250 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 0%125 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 4.8%12.5 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 0% NCT00802438 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a viral upper respiratory tract infection 48.7% headache 28.5% upper respiratory tract infection 23.3% NCT01691859 · Phase 3 · monotherapy show 34 more results75 mg IV nasopharyngitis 22.2% (placebo 15.5%) headache 20.9% (placebo 17.4%) bronchitis 10.5% (placebo 9.7%) NCT01000506 · Phase 2 750 mg IV headache 20.5% (placebo 17.4%) nasopharyngitis 18.6% (placebo 15.5%) infusion related reaction 12.2% (placebo 6.5%) NCT01000506 · Phase 2 250 mg IV nasopharyngitis 21.7% (placebo 15.5%) headache 21.1% (placebo 17.4%) upper respiratory tract infection 11.2% (placebo 9.7%) NCT01000506 · Phase 2 100 mg SC headache 20.3% (placebo 21.2%) nasopharyngitis 14.5% (placebo 15.2%) bronchitis 10.1% (placebo 9.1%) NCT01691508 · Phase 3 100 mg musculoskeletal 4.3% (placebo 0%) nausea, headache, dizzines 2.1% (placebo 8.3%) skin-related symptom 2.1% (placebo 4.2%) NCT04823585 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 26.7% (placebo 40%) NCT04765722 · Phase 4 · registry result, not featured evidence 100 mg SC pyrexia 5% headache 3% oropharyngeal pain 3% NCT04276233 · Phase 4 · registry result, not featured evidence 100 mg SC headache 28.3% viral upper respiratory tract infection 16.6% bronchitis 13.1% NCT02654145 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 40.9% (placebo 41.7%) asthma 30.2% (placebo 54.3%) nasopharyngitis 16.8% (placebo 17.9%) NCT03562195 · Phase 3 · registry result, not featured evidence 100mg SC nasopharyngitis 4.6% (placebo 17.2%) abdominal pain 0% (placebo 0%) arthralgia 0% (placebo 2%) NCT02555371 · Phase 3 · registry result, not featured evidence 100mg nasopharyngitis 18.8% (placebo 17.2%) bronchitis 9.7% (placebo 3.3%) sinusitis 9% (placebo 6%) NCT02555371 · Phase 3 · registry result, not featured evidence 100mg SC nasopharyngitis 20% (placebo 17.2%) bronchitis 17.8% (placebo 3.3%) sinusitis 11.1% (placebo 6%) NCT02555371 · Phase 3 · registry result, not featured evidence 100mg SC nasopharyngitis 19% (placebo 17.2%) asthma 8.3% (placebo 9.3%) bronchitis 8.3% (placebo 3.3%) NCT02555371 · Phase 3 · registry result, not featured evidence nasopharyngitis 5.7% headache 5% upper respiratory tract infection 3.8% NCT03099096 · Phase 3 · registry result, not featured evidence 100 mg SC nasopharyngitis 42.2% bronchitis 18.9% upper respiratory tract infection 18.9% NCT02135692 · Phase 3 · registry result, not featured evidence headache 11.4% viral upper respiratory tract infection 3.8% fatigue 2.5% NCT03014674 · Phase 3 · registry result, not featured evidence headache 10% viral upper respiratory tract infection 7.5% fatigue 1.3% NCT03014674 · Phase 3 · registry result, not featured evidence headache 7.1% fatigue 5.9% viral upper respiratory tract infection 2.4% NCT03014674 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 7.1% NCT03021304 · Phase 3 · registry result, not featured evidence 100 mg SC headache 16.5% (placebo 21.2%) nasopharyngitis 11.4% (placebo 16.5%) upper respiratory tract infection 6.2% (placebo 5%) NCT02281318 · Phase 3 · registry result, not featured evidence 100 mg SC nasopharyngitis 30.1% upper respiratory tract infection 15.2% headache 13.4% NCT01842607 · Phase 3 · registry result, not featured evidence 100 mg SC headache 20.1% (placebo 17.3%) nasopharyngitis 17% (placebo 24.1%) upper respiratory tract infection 12.4% (placebo 14.1%) NCT01691521 · Phase 3 · registry result, not featured evidence 75 mg IV headache 24.1% (placebo 17.3%) nasopharyngitis 23.6% (placebo 24.1%) upper respiratory tract infection 11.5% (placebo 14.1%) NCT01691521 · Phase 3 · registry result, not featured evidence headache 10.3% (placebo 4.9%) injection site reaction 8.9% (placebo 0%) vomiting 8.9% (placebo 8.3%) NCT03292588 · Phase 2 · registry result, not featured evidence 100 mg SC headache 20% acne 10% alanine aminotransferase increased 10% NCT02377427 · Phase 2 · registry result, not featured evidence 100 mg SC bronchitis 30% headache 30% cough 20% NCT02377427 · Phase 2 · registry result, not featured evidence 40/100 mg SC nasopharyngitis 50% abdominal pain 25% adrenal suppression 25% NCT02377427 · Phase 2 · registry result, not featured evidence 40 mg SC injection site reaction 19.2% headache 11.5% nasopharyngitis 11.5% NCT02377427 · Phase 2 · registry result, not featured evidence 40 mg SC bronchitis 31.3% headache 25% influenza 18.8% NCT02377427 · Phase 2 · registry result, not featured evidence 75 mg IV arthralgia 18.2% asthma 9.1% back pain 9.1% NCT01366521 · Phase 2 · registry result, not featured evidence 250 mg SC headache 8.7% nasopharyngitis 8.7% abdominal distension 4.3% NCT01366521 · Phase 2 · registry result, not featured evidence 125 mg SC injection site reaction 20% asthma 6.7% dermatitis atopic 6.7% NCT01366521 · Phase 2 · registry result, not featured evidence 12.5 mg SC asthma 19% injection site reaction 14.3% nasopharyngitis 14.3% NCT01366521 · Phase 2 · registry result, not featured evidence upper respiratory infection 10.5% back pain 2.6% erythema 2.6% NCT00802438 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Mepolizumab
show 17 more results
show 9 more results
show 5 more results
show 8 more results
show 4 more results
show 8 more results
show 2 more results
show 8 more results
show 51 more results
show 38 more results
+ 36 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT2606's landscape · Mepolizumab's landscape